Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Duodenal Neoplasms 1Colorectal Neoplasms 1Barrett Esophagus 1Attenuated familial adenomatous polyposis 1Adenomatous Polyposis Coli 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 14Nivolumab 13Oxaliplatin 12Leucovorin 11Paclitaxel 7Capecitabine 7pembrolizumab 6Radiotherapy 5Cisplatin 5Taxes 4Specimen Handling 4Radiation 4Irinotecan 4Drug Therapy 4dehydroftorafur 3Trastuzumab 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3zimberelimab 2zanidatamab 2trastuzumab deruxtecan 2futibatinib 2Levoleucovorin 2Endoscopy, Digestive System 2Endoscopy 2Carboplatin 2Biopsy 2zolbetuximab 1trastuzumab biosimilar HLX02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × obeticholic acid × 90 days × Clear all
NCT04939051 2026-05-13

Obeticholic Acid for Prevention in Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡